Business Context and Reporting Period
Company: Biozone Pharmaceuticals, Inc. (formerly International Surf Resorts, Inc.)
Filing Date: May 16, 2011
Reporting Period: Current Report on Form 8-K covering the acquisition of Aero Pharmaceuticals, Inc. ("Aero") and the cessation of shell company status.
On May 16, 2011, Biozone Pharmaceuticals, Inc. completed the acquisition of the assets and liabilities of Aero Pharmaceuticals, Inc., a Florida corporation. This transaction marks a strategic pivot from the company's former business of operating international surf resorts to a focus on the manufacturing, marketing, and distribution of dermatological products under the trade name "Baker Cummins Dermatologicals." The acquisition was structured as a tax-free reorganization under Section 368(a) of the Internal Revenue Code. As a result of this transaction, the Company ceased to be a "shell" company as defined by Rule 12b-2 of the Exchange Act.
Key Financial Metrics
The following financial data pertains to the acquired entity, Aero Pharmaceuticals, Inc., for the fiscal years ended December 31, 2010 and 2009, as presented in the Management's Discussion and Analysis.
| Financial Metric | Year Ended Dec 31, 2010 | Year Ended Dec 31, 2009 |
|---|---|---|
| Net Sales | $295,379 | $460,181 |
| Cost of Goods Sold | $92,139 | $178,904 |
| Gross Profit | $203,240 | $281,277 |
| Gross Margin | 68.8% | 61.1% |
| General & Administrative Expenses | $219,902 | $549,495 |
| Net Loss | ($100,697) | ($257,390) |
Debt and Liquidity:
On March 29, 2011, prior to the acquisition closing, the Company issued $2,250,000 in secured convertible notes ("Bridge Notes") due September 29, 2011, bearing 10% annual interest. These notes are convertible into securities of a future "Target Transaction" or repayable in cash. The filing does not provide specific cash balance figures for the combined entity as of the closing date, though it notes the assumption of Aero's liabilities, including accrued royalties which were partially settled.
Material Changes Versus Prior Period
- Revenue Decline: Aero's net sales decreased by 35.8% ($164,802) from 2009 to 2010. This was primarily attributed to reduced marketing efforts and inventory shortages of Ultramide products.
- Expense Reduction: General and administrative expenses dropped significantly by 60.0% ($329,593) in 2010 compared to 2009, driven by reductions in management fees, legal fees, and sales & marketing costs.
- Improved Gross Margin: Despite lower sales, the gross profit margin improved from 61.1% in 2009 to 68.8% in 2010. The 2009 margin was negatively impacted by the destruction of approximately $58,000 of expired product.
- Net Loss Improvement: The net loss narrowed from $257,390 in 2009 to $100,697 in 2010. The 2009 loss included a non-recurring gain on the sale of investments of $220,943; excluding this gain, the 2009 loss was $478,333.
- Royalty Obligation Termination: On April 25, 2011, Aero amended its agreement with Ivax Laboratories, Inc., eliminating all continuing royalty obligations after paying $224,000 to satisfy outstanding accrued royalties of $278,460.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy:
The Company intends to carry on Aero's business as its primary line of business, focusing on OTC dermatological products. Growth strategies include adding new customers, developing line extensions, reformulating products, and acquiring new branded products. The Company operates as a "virtual company," outsourcing R&D and manufacturing to third parties while concentrating on marketing.
Unusual Items and Contingencies:
- Stock Issuance: The Company issued 7,724,000 shares of restricted common stock to Aero shareholders. An additional 7,500,000 shares may be issued based on closing date balance sheet adjustments or to cover dissenting shareholder payments.
- Registration Obligations: The Company agreed to file a registration statement for Aero shares within four months of closing (by September 16, 2011) and have it declared effective by December 16, 2011. Failure to meet these deadlines incurs liquidated damages of 1% per month (5% maximum).
- Bridge Notes Penalty: If the Bridge Notes are not prepaid or converted by September 29, 2011, the Company must pay a penalty fee of $100,000. If the Target Transaction has not closed by that date, the Company must pay 150% of the outstanding principal plus interest.
Risk Factors:
- Customer Concentration: Approximately 50% of revenue is generated from three customers. Loss of any of these customers could have a material adverse effect.
- Manufacturing Dependence: The Company relies on a single third-party vendor for manufacturing. Loss of this vendor could disrupt operations.
- Regulatory Compliance: Products are subject to FDA oversight. Non-compliance could result in seizures, recalls, or criminal penalties.
- Liquidity and Financing: The Company is not profitable and may require additional financing. Failure to secure capital could force a cessation of operations.
- Stock Market Status: The stock trades on the OTC Bulletin Board and may be subject to "penny stock" rules, limiting liquidity. Listing on a national exchange is not guaranteed.
Important Facts for Investor Verification
- Acquisition Terms: Verify the final closing date balance sheet to determine if additional shares (up to 7,500,000) will be issued to Aero shareholders.
- Debt Maturity: Confirm the status of the $2,250,000 Bridge Notes due September 29, 2011, and the Company's ability to refinance or convert them to avoid the 150% repayment penalty.
- Registration Timeline: Monitor the filing and effectiveness of the registration statement for Aero shares to avoid liquidated damages.
- Customer Concentration: Assess the stability of the three major customers representing 50% of revenue.
- Related Party Transactions: Note that key management (Roberto Prego-Novo) and major shareholders (Phillip Frost) hold significant stakes in both the Company and the acquired entity, Aero.